Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;26(6):352-360.
doi: 10.1007/s12471-018-1119-z.

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation

S P G van Vugt  1 , M A Brouwer  2
Affiliations
Review

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation

S P G van Vugt et al. Neth Heart J. 2018 Jun.

Abstract

In this manuscript, we discuss the most important changes in the field of anticoagulant treatment in patients with atrial fibrillation in the setting of electrical cardioversion or catheter ablation. Moreover, we provide practical guidance as well as information on daily practice.

Keywords: Atrial fibrillation; Catheter ablation; Electrical cardioversion; Non-vitamin K oral anticoagulant; Vitamin K antagonist.

PubMed Disclaimer

Conflict of interest statement

S.P.G. van Vugt has received consulting fees/honorariums from Bayer, Boehringer Ingelheim, Bristol-Meyers-Squibb/Pfizer and Daiichi Sankyo and M.A. Brouwer has received consulting fees/honorariums from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers-Squibb/Pfizer and Daiichi Sankyo.

Figures

Fig. 1
Fig. 1
Pericardioversion anticoagulation: key recommendations in the ESC 2016 AF guidelines (ESC European Society of Cardiology, AF atrial fibrillation, AC anticoagulation, UFH unfractionated heparin, LMWH low-molecular-weight heparin, NOAC non-vitamin K oral anticoagulant, VKA vitamin K antagonist, CHA2DS2-VASc score Congestive heart failure, Hypertension, Age ≥ 75 [doubled], Diabetes, prior Stroke [doubled]—Vascular disease, Age 65–74, Sex category, TEE transoesophageal echocardiography)
None
See this image and copyright information in PMC

References

    1. Crijns HJ, Weijs B, Fairley AM, et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol. 2014;172(3):588–594. doi: 10.1016/j.ijcard.2014.01.099. - DOI - PubMed
    1. Bellone A, Etteri M, Vettorello M, et al. Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial. Emerg Med J. 2012;29(3):188–191. doi: 10.1136/emj.2010.109702. - DOI - PubMed
    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Letelier LM, Udol K, Ena J, et al. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch. Intern. Med. 2003;163(7):777–785. doi: 10.1001/archinte.163.7.777. - DOI - PubMed
    1. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2012;26(2):167–179. doi: 10.1007/s10557-012-6374-4. - DOI - PubMed

LinkOut - more resources